CA1089453A - Rifamycin compounds - Google Patents
Rifamycin compoundsInfo
- Publication number
- CA1089453A CA1089453A CA304,380A CA304380A CA1089453A CA 1089453 A CA1089453 A CA 1089453A CA 304380 A CA304380 A CA 304380A CA 1089453 A CA1089453 A CA 1089453A
- Authority
- CA
- Canada
- Prior art keywords
- coch3
- rifamycin
- process according
- radical
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 5
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 125000001589 carboacyl group Chemical group 0.000 claims abstract 3
- -1 1,3-dimethyl-butyl Chemical group 0.000 claims description 41
- QBRFPWPICDILII-WVKYYCEASA-N 3-amino-4-iminorifamycin-s Chemical compound O=C1C(C(O)=C2C)=C3C(N)=C(N)C1=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O QBRFPWPICDILII-WVKYYCEASA-N 0.000 claims description 25
- 229930189077 Rifamycin Natural products 0.000 claims description 19
- 229960003292 rifamycin Drugs 0.000 claims description 19
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 claims description 8
- GTEUDVZENMLOPB-UHFFFAOYSA-N 1-pentylpiperidin-4-one Chemical compound CCCCCN1CCC(=O)CC1 GTEUDVZENMLOPB-UHFFFAOYSA-N 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 150000003254 radicals Chemical group 0.000 claims description 4
- OCNWYKFGWLGNHZ-UHFFFAOYSA-N 1-butylpiperidin-4-one Chemical compound CCCCN1CCC(=O)CC1 OCNWYKFGWLGNHZ-UHFFFAOYSA-N 0.000 claims description 3
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 3
- ULOIAOPTGWSNHU-UHFFFAOYSA-N 2-butyl radical Chemical group C[CH]CC ULOIAOPTGWSNHU-UHFFFAOYSA-N 0.000 claims description 3
- MSUAFFBEKJQZIC-UHFFFAOYSA-N 2-chloroethanone Chemical group ClC[C]=O MSUAFFBEKJQZIC-UHFFFAOYSA-N 0.000 claims description 3
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical group [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 claims description 3
- GAKRFXBXTBSAOJ-UHFFFAOYSA-N 1-(2,2-dimethylpropanoyl)piperidin-4-one Chemical compound CC(C)(C)C(=O)N1CCC(=O)CC1 GAKRFXBXTBSAOJ-UHFFFAOYSA-N 0.000 claims description 2
- OJEDWBCGPOCKJW-UHFFFAOYSA-N 1-cyclopentylpiperidin-4-one Chemical compound C1CC(=O)CCN1C1CCCC1 OJEDWBCGPOCKJW-UHFFFAOYSA-N 0.000 claims description 2
- NUWRORAIHKGQGZ-UHFFFAOYSA-N 1-pentan-3-ylpiperidin-4-one Chemical compound CCC(CC)N1CCC(=O)CC1 NUWRORAIHKGQGZ-UHFFFAOYSA-N 0.000 claims description 2
- YGDZKYYCJUNORF-UHFFFAOYSA-N 1-propylpiperidin-4-one Chemical compound CCCN1CCC(=O)CC1 YGDZKYYCJUNORF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 18
- MYAIXBLYHLPLBX-UHFFFAOYSA-N 1-(2-methyloxolan-2-yl)piperidin-4-one Chemical compound C1CC(=O)CCN1C1(C)CCCO1 MYAIXBLYHLPLBX-UHFFFAOYSA-N 0.000 claims 1
- HIVGHZXGBOWBKY-UHFFFAOYSA-N 1-(3-methylfuran-2-yl)piperidin-4-one Chemical compound C1=COC(N2CCC(=O)CC2)=C1C HIVGHZXGBOWBKY-UHFFFAOYSA-N 0.000 claims 1
- NUPCXPOFGHXLIZ-UHFFFAOYSA-N 1-hexylpiperidin-4-one Chemical compound CCCCCCN1CCC(=O)CC1 NUPCXPOFGHXLIZ-UHFFFAOYSA-N 0.000 claims 1
- YVGBIRJOKAAAFW-UHFFFAOYSA-N 1-octylpiperidin-4-one Chemical compound CCCCCCCCN1CCC(=O)CC1 YVGBIRJOKAAAFW-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 13
- 239000011701 zinc Substances 0.000 description 13
- 229910052725 zinc Inorganic materials 0.000 description 13
- 238000001663 electronic absorption spectrum Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000005695 Ammonium acetate Substances 0.000 description 8
- 229940043376 ammonium acetate Drugs 0.000 description 8
- 235000019257 ammonium acetate Nutrition 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- BDVKAMAALQXGLM-UHFFFAOYSA-N 1-ethylpiperidin-4-one Chemical compound CCN1CCC(=O)CC1 BDVKAMAALQXGLM-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- JQKIHHHTOFFTAM-UHFFFAOYSA-N piperidin-4-one;hydrate Chemical compound O.O=C1CCNCC1 JQKIHHHTOFFTAM-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2825445A DE2825445C2 (de) | 1975-06-13 | 1978-06-09 | Rifamycin-S-Verbindungen und Verfahren zu ihrer Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1089453A true CA1089453A (en) | 1980-11-11 |
Family
ID=6041475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA304,380A Expired CA1089453A (en) | 1978-06-09 | 1978-05-30 | Rifamycin compounds |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS557203A (enrdf_load_stackoverflow) |
| BE (1) | BE870570R (enrdf_load_stackoverflow) |
| CA (1) | CA1089453A (enrdf_load_stackoverflow) |
| CH (1) | CH633014A5 (enrdf_load_stackoverflow) |
| FR (1) | FR2426690A2 (enrdf_load_stackoverflow) |
| GB (1) | GB1603127A (enrdf_load_stackoverflow) |
| NL (2) | NL182564C (enrdf_load_stackoverflow) |
| SE (1) | SE441751B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106279205A (zh) * | 2015-05-12 | 2017-01-04 | 重庆华邦胜凯制药有限公司 | 制备利福霉素s衍生物的方法 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1154655B (it) * | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
| WO2008008480A2 (en) * | 2006-07-12 | 2008-01-17 | Cumbre Pharmaceuticals Inc. | Nitroheteroaryl-containing rifamycin derivatives |
| US7884099B2 (en) | 2007-11-16 | 2011-02-08 | Cumbre Ip Ventures, L.P. | Quinolone carboxylic acid-substituted rifamycin derivatives |
| RU2496475C2 (ru) | 2011-10-26 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция и набор для лечения бактериальных инфекций |
| CN103408571B (zh) * | 2013-08-23 | 2015-11-18 | 成都樵枫科技发展有限公司 | 利福布丁的晶型i及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1056271B (it) * | 1975-05-20 | 1982-01-30 | Archifar Ind Chim Trentino | Prodotti derivati dalle amine aromatiche |
| DK345977A (da) * | 1976-09-30 | 1978-03-31 | Archifar Ind Chim Trentino | G rifamycinforbindelser og fremgangsmaade til deres fremstillin |
-
1978
- 1978-05-22 CH CH554478A patent/CH633014A5/it not_active IP Right Cessation
- 1978-05-23 SE SE7805863A patent/SE441751B/sv not_active IP Right Cessation
- 1978-05-24 GB GB22170/78A patent/GB1603127A/en not_active Expired
- 1978-05-24 FR FR7815450A patent/FR2426690A2/fr active Granted
- 1978-05-30 CA CA304,380A patent/CA1089453A/en not_active Expired
- 1978-06-20 NL NLAANVRAGE7806659,A patent/NL182564C/xx not_active IP Right Cessation
- 1978-06-27 JP JP7706378A patent/JPS557203A/ja active Granted
- 1978-09-18 BE BE190561A patent/BE870570R/xx active
-
1995
- 1995-11-22 NL NL950028C patent/NL950028I2/nl unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106279205A (zh) * | 2015-05-12 | 2017-01-04 | 重庆华邦胜凯制药有限公司 | 制备利福霉素s衍生物的方法 |
| CN106279205B (zh) * | 2015-05-12 | 2020-07-21 | 重庆华邦胜凯制药有限公司 | 制备利福霉素s衍生物的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| BE870570R (fr) | 1979-01-15 |
| FR2426690A2 (fr) | 1979-12-21 |
| JPH0114238B2 (enrdf_load_stackoverflow) | 1989-03-10 |
| SE7805863L (sv) | 1979-11-24 |
| FR2426690B2 (enrdf_load_stackoverflow) | 1982-05-28 |
| JPS557203A (en) | 1980-01-19 |
| NL950028I2 (nl) | 1997-04-01 |
| NL182564C (nl) | 1988-04-05 |
| NL7806659A (nl) | 1979-12-27 |
| GB1603127A (en) | 1981-11-18 |
| NL950028I1 (nl) | 1996-03-01 |
| SE441751B (sv) | 1985-11-04 |
| NL182564B (nl) | 1987-11-02 |
| CH633014A5 (en) | 1982-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU902666A3 (ru) | Способ получени плевромутилиновых гликозидных производных | |
| US10179775B2 (en) | Cyclooctenes for bioorthogonol reactions | |
| DE69507702T2 (de) | Semisynthetisch taxal derivate mit antitumor wirkung | |
| US4584369A (en) | Anti-leukemic beta-glycosyl C-nucleosides | |
| DE2844292A1 (de) | Pyrrolobenzodiazepine, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von tumorerkrankungen | |
| IE61018B1 (en) | Improved process for preparing macrolide derivatives | |
| CA1306248C (en) | Androstane-17-carboxylic acid esters process for their preparation and medecine containing them | |
| CA1089453A (en) | Rifamycin compounds | |
| EP0071227B1 (en) | Anti-leukemic beta-glycosyl c-nucleosides | |
| JPS6345293A (ja) | シアロシルセラミド類及びその製造方法 | |
| AT392793B (de) | Verfahren zur herstellung von neuen anthracyclinglykosiden | |
| SU993822A3 (ru) | Способ получени гликозидов антрациклина | |
| CA1315278C (fr) | Derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, et leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| DE2832127C2 (de) | 1-(2-Chloräthyl)-1-nitroso-3-substituierte-3-glycosylharnstoffe, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen | |
| GB1564807A (en) | Cholestene derivatives | |
| DK152133B (da) | Analogifremgangsmaade til fremstilling af oleandomycinderivater eller farmaceutisk acceptable syreadditionssalte deraf | |
| DE69904294T2 (de) | Cytotoxische tris oxazole makrolide | |
| JPS62135490A (ja) | 宿主抵抗性促進剤としてのステロイド性グリコリピド | |
| TAKAMIZAWA et al. | Studies on Pyrimidine Derivatives and Related Compounds. LXXV. Reactions of Thiazolium Salts with Diethyl Acylphosphonates and Hydroxylation of Some 3-Oxo-2, 3-dihydro-4H-1, 4-thiazine Derivatives | |
| DE3688364T2 (de) | Steroidische Glycolipide als Immunstimulatoren. | |
| KR820000546B1 (ko) | 리파마이신화합물의 제조방법 | |
| US4849409A (en) | Diels-alder adduct from streptazoline and naphthoquinones and its oxidation products, which have cytotoxic and antimicrobial activity and which act against protozoa | |
| IE46900B1 (en) | Rifamycin compounds | |
| Adamiak et al. | Absolute Configuration of the Cancerostatic S (–)‐Isophosphamide | |
| DE2917890A1 (de) | 1,6-di-(0-methansulfonyl)-3,4-di- (0-methyl)-d-mannit, verfahren zu seiner herstellung und diesen enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |